Trauma and Multiple Sclerosis:A Population-Based Cohort Study from Olmsted County, Minnesota
Neurol 43:1878-1882, 18711993., Siva,A.,et al, 1993
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002